Pub Date : 2022-04-02DOI: 10.37022/wjcmpr.v4i2.208
Mary Supriya G, Abhishekar M, B. B, Meghana Ch, P. P, S. B
As per ICH GCP, monitoring can be defined as “The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).” Clinical experiments are important for deeper understanding of how interventions work in humans. The aim of the monitoring of the clinical trial is to avoid errors that may compromise patient safety and results of the trial and enables more frequent monitoring of the integrity of the trial and could improve safety concerns by detecting errors earlier than expected. Risk-based monitoring in clinical trials is the process of identification, assessment, monitoring and mitigation of risks that could affect the quality or safety of a study. Centralized monitoring has a direct impact on the clinical trials. One of the most basic and fundamental need of centralized monitoring is to avoid the repetition in clinical trials, saving both time and Money. Central monitoring greatly influences the Patient safety, data integrity and monitoring costs in a clinical trial. This helps in increasing the effectiveness of the monitoring process reducing the burden on the sponsor. The basic and fundamental priority of a clinical trial is to ensure the safety and well-being of the subject. In this article, we will be focusing on how Centralized monitoring can increase the effectiveness and efficiency of the monitoring process and source data verification (SDV) in clinical trials with a special emphasis on Risk based monitoring (RBM)
{"title":"Reliability and feasibility of centralized monitoring approach in source data verification during clinical trials","authors":"Mary Supriya G, Abhishekar M, B. B, Meghana Ch, P. P, S. B","doi":"10.37022/wjcmpr.v4i2.208","DOIUrl":"https://doi.org/10.37022/wjcmpr.v4i2.208","url":null,"abstract":"As per ICH GCP, monitoring can be defined as “The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).” Clinical experiments are important for deeper understanding of how interventions work in humans. The aim of the monitoring of the clinical trial is to avoid errors that may compromise patient safety and results of the trial and enables more frequent monitoring of the integrity of the trial and could improve safety concerns by detecting errors earlier than expected. Risk-based monitoring in clinical trials is the process of identification, assessment, monitoring and mitigation of risks that could affect the quality or safety of a study. Centralized monitoring has a direct impact on the clinical trials. One of the most basic and fundamental need of centralized monitoring is to avoid the repetition in clinical trials, saving both time and Money. Central monitoring greatly influences the Patient safety, data integrity and monitoring costs in a clinical trial. This helps in increasing the effectiveness of the monitoring process reducing the burden on the sponsor. The basic and fundamental priority of a clinical trial is to ensure the safety and well-being of the subject. In this article, we will be focusing on how Centralized monitoring can increase the effectiveness and efficiency of the monitoring process and source data verification (SDV) in clinical trials with a special emphasis on Risk based monitoring (RBM)","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"93 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88549185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-08DOI: 10.37022/wjcmpr.v4i1.205
Laddimath Arati
An ethnomedicinal plant species survey of the Vijayapur district of Karnataka comprising thirteen talukas was conducted from March 2018 to July 2021. The purpose of this survey was to document the Ethnomedicinal plant species used for animal and insect bites. The present study was initiated with an aim to identify Ethno-medicinal plant species resources from traditional practitioners of the Vijayapur district. There are about 21 plant species of angiosperms belonging to 20 genera and 15 families were found to be used as animal and insect bites.
{"title":"Ethno-medicinal plant species used for animal and insect bite (sting) of vijayapur(bijapur) district of karnataka, India","authors":"Laddimath Arati","doi":"10.37022/wjcmpr.v4i1.205","DOIUrl":"https://doi.org/10.37022/wjcmpr.v4i1.205","url":null,"abstract":"An ethnomedicinal plant species survey of the Vijayapur district of Karnataka comprising thirteen talukas was conducted from March 2018 to July 2021. The purpose of this survey was to document the Ethnomedicinal plant species used for animal and insect bites. The present study was initiated with an aim to identify Ethno-medicinal plant species resources from traditional practitioners of the Vijayapur district. There are about 21 plant species of angiosperms belonging to 20 genera and 15 families were found to be used as animal and insect bites.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"130 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79605485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-08DOI: 10.37022/wjcmpr.v3i6.206
Manisha, A. Singh, A. Singh
Ficus thonningii is an African ethnomedicine plant used to treat a number of diseases. The nutritional, phytochemical, and pharmacological aspects of F. thonningii in relation to its therapeutic purposes are numerous. Ficus thonningii contains alkaloids, terpenoids, flavonoids, tannins, active proteins, and active proteins. Continue to identify, isolate, and quantify the active ingredients, as well as their medicinal purposes. Chronic toxicity, toxicology, antineoplastic effects, acute toxicity, hypoglycemic effects, antidiarrheal effects, analgesic effects, anti-inflammatory effects, antioxidants, antifungal activity, antimicrobial effects, antiprotozoal properties etc.
{"title":"Pharmacological profile of ficus thonningii: a review","authors":"Manisha, A. Singh, A. Singh","doi":"10.37022/wjcmpr.v3i6.206","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.206","url":null,"abstract":"Ficus thonningii is an African ethnomedicine plant used to treat a number of diseases. The nutritional, phytochemical, and pharmacological aspects of F. thonningii in relation to its therapeutic purposes are numerous. Ficus thonningii contains alkaloids, terpenoids, flavonoids, tannins, active proteins, and active proteins. Continue to identify, isolate, and quantify the active ingredients, as well as their medicinal purposes. Chronic toxicity, toxicology, antineoplastic effects, acute toxicity, hypoglycemic effects, antidiarrheal effects, analgesic effects, anti-inflammatory effects, antioxidants, antifungal activity, antimicrobial effects, antiprotozoal properties etc.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90152434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-07DOI: 10.37022/wjcmpr.v3i6.200
M. Khadka, D. Khanal, Deeptipiya Baniya, Prakat Karki, S. Shrestha
Orally disintegrating tablets of Furosemide were prepared, evaluated and the comparison of the action of different concentrations of disintegrants on disintegration and dissolution of the tablets were studied. Direct compression method was used to prepare the orally disintegrating tablets containing 20 mg of Furosemide. The formulation was conducted using different concentrations of crospovidone, croscarmellose and sodium starch glycolate as superdisintegrants and their interactions with Furosemide were also evaluated using FTIR. FTIR studies using the drug and its mixtures with the excipients showed that the peaks correlate with one another which signify that there is no interaction between the drug molecule and the excipients used. The obtained results revealed that the disintegration time of ODTs were between 9 to 59 seconds. The percentage drug content of tablets in all the formulations was found between 91.51% to 106.69%, which complies with the limits established in pharmacopoeia. The in-vitro dissolution studies show maximum release of 89.47% in formulation F3 and minimum of 77.64% in formulation F12. Higher concentration of crospovidone and croscarmellose in formulations F3 and F6 showed better dissolution properties than SSG. So by varying the concentrations of superdisintegrants, oral disintegrating tablets can be formulated.
{"title":"Formulation and evaluation of oral disintegrating tablets of furosemide","authors":"M. Khadka, D. Khanal, Deeptipiya Baniya, Prakat Karki, S. Shrestha","doi":"10.37022/wjcmpr.v3i6.200","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.200","url":null,"abstract":"Orally disintegrating tablets of Furosemide were prepared, evaluated and the comparison of the action of different concentrations of disintegrants on disintegration and dissolution of the tablets were studied. Direct compression method was used to prepare the orally disintegrating tablets containing 20 mg of Furosemide. The formulation was conducted using different concentrations of crospovidone, croscarmellose and sodium starch glycolate as superdisintegrants and their interactions with Furosemide were also evaluated using FTIR. FTIR studies using the drug and its mixtures with the excipients showed that the peaks correlate with one another which signify that there is no interaction between the drug molecule and the excipients used. The obtained results revealed that the disintegration time of ODTs were between 9 to 59 seconds. The percentage drug content of tablets in all the formulations was found between 91.51% to 106.69%, which complies with the limits established in pharmacopoeia. The in-vitro dissolution studies show maximum release of 89.47% in formulation F3 and minimum of 77.64% in formulation F12. Higher concentration of crospovidone and croscarmellose in formulations F3 and F6 showed better dissolution properties than SSG. So by varying the concentrations of superdisintegrants, oral disintegrating tablets can be formulated.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89176016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-07DOI: 10.37022/wjcmpr.v3i6.204
T. R. Ogoun, Tobia P.S S, A. T. T
Human body parts are useful in the predictive study of the unknown. The aim of this study is to know the normative values of the canthi of the Ekowe people. Measurements such as inner and outer canthal distances were carried out. The mean value of the innercanthal distance for males and females are 3.55±0.58 and 3.43±0.52. The mean outer canthal distance for male and female is 13.91±0.84 and 13.62±0.76. The canthal index for male and female is 25.59±4.54 and 25.30±4.03. Sexual dimorphism exists and statistical significant difference was noticed in the outer canthal distance between the males and females (P˂0.05). This study has provided us with normative reference values of inner and outer canthal distances and canthal index for the Ekowe Population which is import to the health care givers, Anatomist, ophthalmic industry and anthropologist
{"title":"a comparative analysis of canthal index of ekowe indigenes, bayelsa state","authors":"T. R. Ogoun, Tobia P.S S, A. T. T","doi":"10.37022/wjcmpr.v3i6.204","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.204","url":null,"abstract":"Human body parts are useful in the predictive study of the unknown. The aim of this study is to know the normative values of the canthi of the Ekowe people. Measurements such as inner and outer canthal distances were carried out. The mean value of the innercanthal distance for males and females are 3.55±0.58 and 3.43±0.52. The mean outer canthal distance for male and female is 13.91±0.84 and 13.62±0.76. The canthal index for male and female is 25.59±4.54 and 25.30±4.03. Sexual dimorphism exists and statistical significant difference was noticed in the outer canthal distance between the males and females (P˂0.05). This study has provided us with normative reference values of inner and outer canthal distances and canthal index for the Ekowe Population which is import to the health care givers, Anatomist, ophthalmic industry and anthropologist","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"158 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86346662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-06DOI: 10.37022/wjcmpr.v3i6.202
Nensi Raytthatha, Isha Shah, Jigar Vyas
Cystic fibrosis (CF) is one of the most deadly diseases of lungs that involves symptoms such as breathing difficulties, coughing and lung infection. Despite important therapeutic advances, the definitive treatment for CF remains elusive. CF is a good candidate for gene therapy because it is relatively common, lethal and monogenic and it does not have adequate treatment options. In this review article, we have reviewed gene therapy as a potential treatment option for CF. Various platforms and strategies for pulmonary gene delivery have also been discussed in detail.
{"title":"Pulmonary delivery of sirna for the treatment of cystic fibrosis and pulmonary delivery platforms","authors":"Nensi Raytthatha, Isha Shah, Jigar Vyas","doi":"10.37022/wjcmpr.v3i6.202","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.202","url":null,"abstract":"Cystic fibrosis (CF) is one of the most deadly diseases of lungs that involves symptoms such as breathing difficulties, coughing and lung infection. Despite important therapeutic advances, the definitive treatment for CF remains elusive. CF is a good candidate for gene therapy because it is relatively common, lethal and monogenic and it does not have adequate treatment options. In this review article, we have reviewed gene therapy as a potential treatment option for CF. Various platforms and strategies for pulmonary gene delivery have also been discussed in detail.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86141992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-28DOI: 10.37022/wjcmpr.v3i6.201
S. M, L. S, M. A, Sailaja K.E
This study aims to extract the phytochemical constituents and in-vitro evaluation of anti-inflammatory activity of roots of clerodendrum Indicum. Clerodendrum indicum (L.) kuntz. Commonly known as bharangi or chingari, belongs to the family verbenaceae. The plant is expectorant, stomachic, Anti-bronchitis, Anti-nociceptive, Anti-microbial, Anti-diarrheal, anti-oxidant and anti-cancer. Preliminary phytochemical screening revealed the presence of flavonoids, steroids, steroid glycosides, terpenoids etc. This study has taken with the Anti-inflammatory activity and preliminary phytochemical screening on the clerodendrum indicum. In the present study, qualitative study of the phytochemicals present in the sample was determined, Anti-inflammatory activity were carried out. On the premise of the prevailing study, the outcomes eventually concluded that the ethanolic extract of clerodendrum indicum own anti inflammatory pastime. This evaluation offers an concept that the compound of the plant clerodendrum indicum may be used as lead compound for designing robust pills which may be used for remedy of diverse diseases.
{"title":"Phytochemical screening & in-vitro evaluation of anti-inflammatory activity of clerodendrum indicum roots","authors":"S. M, L. S, M. A, Sailaja K.E","doi":"10.37022/wjcmpr.v3i6.201","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.201","url":null,"abstract":"This study aims to extract the phytochemical constituents and in-vitro evaluation of anti-inflammatory activity of roots of clerodendrum Indicum. Clerodendrum indicum (L.) kuntz. Commonly known as bharangi or chingari, belongs to the family verbenaceae. The plant is expectorant, stomachic, Anti-bronchitis, Anti-nociceptive, Anti-microbial, Anti-diarrheal, anti-oxidant and anti-cancer. Preliminary phytochemical screening revealed the presence of flavonoids, steroids, steroid glycosides, terpenoids etc. This study has taken with the Anti-inflammatory activity and preliminary phytochemical screening on the clerodendrum indicum. In the present study, qualitative study of the phytochemicals present in the sample was determined, Anti-inflammatory activity were carried out. On the premise of the prevailing study, the outcomes eventually concluded that the ethanolic extract of clerodendrum indicum own anti inflammatory pastime. This evaluation offers an concept that the compound of the plant clerodendrum indicum may be used as lead compound for designing robust pills which may be used for remedy of diverse diseases.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"122 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89405776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-17DOI: 10.37022/wjcmpr.v3i6.197
Nomane Bernard Goze, K. Léandre, N. OussouN’GuessanJean-BaptisteOussou, Ehile Ehile Herve, Koffi Kouassi Bah Abel, Y. Paul
Macaranga barteri is a plant used in traditional medicine to treat non-alcoholic fatty liver disease. However, its potential against hepatic steatosis has not been scientifically proven yet. This work aimed to investigate the preventive effect of the aqueous extract of Macaranga barteri leaves (AEMb) on hepatic steatosis experimentally induced with amiodarone in rats. 36 rats were divided into 6 groups of 6 rats each. Group 1, the non-intoxicated group and Group 2, used as controls were pretreated with distilled water (10 ml/kg b.w.). Group 3 received silymarin at 100 mg/kg b.w. while Groups 4, 5 and 6 were pretreated with AEMb at doses of 125, 250 and 500 mg/kg b.w. respectively. The weights of the rats were monitored during the experimentation. After 7 days of daily pretreatment with the different substances, rats of groups 2 to 6 were administered intraperitoneally amiodarone (200 mg/kg bw) three times daily for seven other consecutive days. At the end of the experiments, blood samples were collected on fasted and anesthetized rats kept in dried and EDTA tubes in order to assess some hematological and biochemical parameters and also rats livers were removed for gross observation and hepatic triglyceride assessment. The results revealed that AEMb and silymarin inhibited the weight loss induced by amiodarone and even favored weight gain. The reduction of heamatological indices (leukocytes and leukocyte indices, erythrocytes and erythrocyte indices (MCV, MCH and MCHC), hemoglobin, hematocrit and thrombocytes) by amiodarone was impeded in AEMb treated rats. AEMb significantly reduced (p <0.001) lipid profile parameters (plasma triglycerides, cholesterols (LDL, HDL and total)) augmented by amiodarone. Increased hepatic parameters (alkaline phosphatase, bilirubins (total and conjugated), transaminases (AST and ALT)) elicited by amiodarone were restored by AEMb pretreatment while decreased HDL values were normalized as well. Silymarin and AEMb also restored livers appearance and hepatic triglyceride. In conclusion, AEMb have a real preventive potential against amiodarone induced-hepatic steatosis in rats.
{"title":"Preventive effect of Macaranga barteri Mül Arg. (Euphorbiaceae) aqueous leaf extract on amiodarone induced non-alcoholic fatty liver disease in rats","authors":"Nomane Bernard Goze, K. Léandre, N. OussouN’GuessanJean-BaptisteOussou, Ehile Ehile Herve, Koffi Kouassi Bah Abel, Y. Paul","doi":"10.37022/wjcmpr.v3i6.197","DOIUrl":"https://doi.org/10.37022/wjcmpr.v3i6.197","url":null,"abstract":"Macaranga barteri is a plant used in traditional medicine to treat non-alcoholic fatty liver disease. However, its potential against hepatic steatosis has not been scientifically proven yet. This work aimed to investigate the preventive effect of the aqueous extract of Macaranga barteri leaves (AEMb) on hepatic steatosis experimentally induced with amiodarone in rats. 36 rats were divided into 6 groups of 6 rats each. Group 1, the non-intoxicated group and Group 2, used as controls were pretreated with distilled water (10 ml/kg b.w.). Group 3 received silymarin at 100 mg/kg b.w. while Groups 4, 5 and 6 were pretreated with AEMb at doses of 125, 250 and 500 mg/kg b.w. respectively. The weights of the rats were monitored during the experimentation. After 7 days of daily pretreatment with the different substances, rats of groups 2 to 6 were administered intraperitoneally amiodarone (200 mg/kg bw) three times daily for seven other consecutive days. At the end of the experiments, blood samples were collected on fasted and anesthetized rats kept in dried and EDTA tubes in order to assess some hematological and biochemical parameters and also rats livers were removed for gross observation and hepatic triglyceride assessment. The results revealed that AEMb and silymarin inhibited the weight loss induced by amiodarone and even favored weight gain. The reduction of heamatological indices (leukocytes and leukocyte indices, erythrocytes and erythrocyte indices (MCV, MCH and MCHC), hemoglobin, hematocrit and thrombocytes) by amiodarone was impeded in AEMb treated rats. AEMb significantly reduced (p <0.001) lipid profile parameters (plasma triglycerides, cholesterols (LDL, HDL and total)) augmented by amiodarone. Increased hepatic parameters (alkaline phosphatase, bilirubins (total and conjugated), transaminases (AST and ALT)) elicited by amiodarone were restored by AEMb pretreatment while decreased HDL values were normalized as well. Silymarin and AEMb also restored livers appearance and hepatic triglyceride. In conclusion, AEMb have a real preventive potential against amiodarone induced-hepatic steatosis in rats.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88933343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-16DOI: 10.37022/WJCMPR.V3I5.194
E. Mohammad, A. Kushwaha
Plants have been use for the treatment, mitigation and cure of the disease since time immemorial. The natural recourses are considered as safe for human use. Ayurveda advocates the Jatamansi in various human ailments. In the present review article we tried to establish the morphological, ehno-pharmacological and therapeutic aspect of the Jatamansi. The various search engines like, Google scholar, EMBASE, pub med, pub med central are used to search the literary information and published article. We tried to put the facts that are demand of this article and explore the proficiency of the Jatamansi as panacea for various ailments.
自古以来，植物就被用于治疗、缓解和治愈这种疾病。这些自然资源被认为对人类使用是安全的。阿育吠陀在各种人类疾病中提倡Jatamansi。在本文中，我们试图从形态学、药理和治疗等方面对其进行综述。利用谷歌scholar、EMBASE、pub med、pub med central等搜索引擎进行文献信息和发表文章的检索。我们试图把这篇文章所需要的事实和探索的熟练的Jatamansi作为各种疾病的灵丹妙药。
{"title":"Jatamansi (nardostachys jatamansi): insight of its morphological, Ethno-pharmacological and therapeutical aspect","authors":"E. Mohammad, A. Kushwaha","doi":"10.37022/WJCMPR.V3I5.194","DOIUrl":"https://doi.org/10.37022/WJCMPR.V3I5.194","url":null,"abstract":"Plants have been use for the treatment, mitigation and cure of the disease since time immemorial. The natural recourses are considered as safe for human use. Ayurveda advocates the Jatamansi in various human ailments. In the present review article we tried to establish the morphological, ehno-pharmacological and therapeutic aspect of the Jatamansi. The various search engines like, Google scholar, EMBASE, pub med, pub med central are used to search the literary information and published article. We tried to put the facts that are demand of this article and explore the proficiency of the Jatamansi as panacea for various ailments.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88156587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-08DOI: 10.37022/WJCMPR.V3I5.195
I. Made, Bayu Puradipa, Cyndiana Widia, Dewi Sinardja
Background: Pandemic of Coronavirus Disease 2019 (COVID-19) is a world health problem, with rapidly growing infected subjects. Recently, hyponatremia has been found to be associated with increased morbidity and mortality in hospitalized patients with severe acute respiratory syndrome-Coronavirus 2 (SARS-COV2) pneumonia. On the other hand, Acute heart failure (AHF) is a leading cause of hospitalization and readmission in the US. The standard management of AHF is removing the fluid primarily with loop diuretics or ultrafiltration. Unfortunately, the loop diuretics could lead to electrolyte imbalance. Case Description: A Male 71 years old with confirmed COVID-19 came to emergency room with shortness of breath and history of coronary artery disease (CAD). Unfortunately, the infection leads patient to non-ST Elevation Myocardial Infarction (NSTEMI). During the treatment, patient down to acute decompensated heart failure (ADHF). The congestion did not respond to Furosemide 40mg intravenously and Spironolactone 25mg orally. Discussion: Arginine‑vasopressin (AVP) levels are elevated in heart failure. AVP acts via V2 cause fluid retention and hyponatremia. Aquaretic (i.e., Tolvaptan) are antagonists of AVP-2 receptors in the renal tubules to promote solute-free water clearance and correct hyponatremia. Conclusion: Important to avoid hyponatremia to prevent mortality and sepsis in patient COVID-19.
{"title":"Tolvaptan to Achieving High Urine Output and Avoiding Hyponatremia in COVID-19 with ADHF Patient: Case Report","authors":"I. Made, Bayu Puradipa, Cyndiana Widia, Dewi Sinardja","doi":"10.37022/WJCMPR.V3I5.195","DOIUrl":"https://doi.org/10.37022/WJCMPR.V3I5.195","url":null,"abstract":"Background: Pandemic of Coronavirus Disease 2019 (COVID-19) is a world health problem, with rapidly growing infected subjects. Recently, hyponatremia has been found to be associated with increased morbidity and mortality in hospitalized patients with severe acute respiratory syndrome-Coronavirus 2 (SARS-COV2) pneumonia. On the other hand, Acute heart failure (AHF) is a leading cause of hospitalization and readmission in the US. The standard management of AHF is removing the fluid primarily with loop diuretics or ultrafiltration. Unfortunately, the loop diuretics could lead to electrolyte imbalance. \u0000Case Description: A Male 71 years old with confirmed COVID-19 came to emergency room with shortness of breath and history of coronary artery disease (CAD). Unfortunately, the infection leads patient to non-ST Elevation Myocardial Infarction (NSTEMI). During the treatment, patient down to acute decompensated heart failure (ADHF). The congestion did not respond to Furosemide 40mg intravenously and Spironolactone 25mg orally. \u0000Discussion: Arginine‑vasopressin (AVP) levels are elevated in heart failure. AVP acts via V2 cause fluid retention and hyponatremia. Aquaretic (i.e., Tolvaptan) are antagonists of AVP-2 receptors in the renal tubules to promote solute-free water clearance and correct hyponatremia. \u0000Conclusion: Important to avoid hyponatremia to prevent mortality and sepsis in patient COVID-19.","PeriodicalId":23642,"journal":{"name":"World Journal of Current Medical and Pharmaceutical Research","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79726570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：